Navigation Links
New Research from Mount Sinai on Alcohol Could Spur Development of Antidote
Date:10/23/2013

New York, NY (PRWEB) October 23, 2013

Scientists now understand how alcohol alters the activity of brain proteins. Ethanol, the alcohol found in beer, wine, and spirits, impairs communication between nerve cells in the brain, affecting our perception and behavior. Paul A. Slesinger, PhD, Professor in the Arthur M. Fishberg Department of Neuroscience at the Icahn School of Medicine at Mount Sinai and Karthik Bodhinathan, PhD, postdoctoral fellow at the Salk Institute for Biological Studies, La Jolla, CA, examined the physical site for ethanol in a brain ion channel, a protein that controls electrical activity of neurons. Results from their study, published online Oct. 21 in the Proceedings of the National Academy of Sciences, suggest that scientists have a clearer view of ethanol’s action and potentially how to interfere with it.

“Ethanol is an amazingly simple drug chemically, yet scientists have been mystified by how a small molecule exerts such profound effects on the function of brain proteins,” said Dr. Slesinger.

In previous work, Dr. Slesinger identified a trigger site for ethanol located with a brain potassium ion channel, which controls electrical activity for proper nerve cell communication. This new research builds on that work, describing for the first time, used a unique technique of ‘alcohol tagging’ to decipher the molecular mechanism underlying ethanol activation of this brain channel protein. In the new paper, “we also discovered a molecule commonly found in the cell’s membrane that can directly influence how ethanol activates these brain potassium channels,” said Dr. Bodhinathan.

“Now that we know the way ethanol binds to these brain proteins, it may be possible in the future to design drugs that take advantage of the chemical features of this alcohol site,” said Dr. Slesinger. “Designing drugs as an antidote might prove a viable intervention.”

Drs. Slesinger and Bodhinathan believe that their work may extend to other alcohol-sensitive proteins, opening the door to a whole new direction for developing alcohol-selective therapeutics in the treatment of alcoholism and addiction.”

This work was supported by the American Heart Association, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute on Drug Abuse.

About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.

The System includes approximately 6,600 primary and specialty care physicians, 12-minority-owned free-standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report.

For more information, visit http://www.mountsinai.org.
Find Mount Sinai on:
Facebook: http://www.facebook.com/mountsinainyc
Twitter @mountsinainyc
YouTube: http://www.youtube.com/mountsinainy

Read the full story at http://www.prweb.com/releases/2013/10/prweb11261461.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Neurotoxin effectively relieves bone cancer pain in dogs, Penn researchers find
2. Bradley Hasbro Childrens Research Center launches food allergy video game trial
3. Global Nitrogenous Fertilizer Market to 2017 is the New Research Report Available with ReportsnReports.com
4. Fred Hutchinson Cancer Research Center opens HIV-vaccine lab in South Africa
5. Postherpetic Neuralgia Market (PHN) Analysis and 2022 Forecasts in New Research Report at RnRMarketResearch.com
6. Research and Development Forecast of High Voltage DC Power Supply in China, 2013-2017
7. Research and Forecast of China’s Dietary Supplement (Health Food) Industry, 2013-2017
8. Gates Foundation and Mayo Clinic Experts to Address Vaccine Research in the 21st Century
9. Redressing Past Wrongs: Changing the Common Rule to Increase Minority Voices in Research
10. Medical & Surgical Equipment Repair Procurement Research Report Now Available from IBISWorld
11. Mount Sinai Researchers Find Value -- and Limitations -- of Patient Assistance Programs for Women with Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
Breaking Medicine Technology: